Trials / Completed
CompletedNCT00801437
Non Interventional Study With Primary Open Angle Glaucoma and/or Ocular Hypertension Patients Treated With Xalacom® After Failure of Previous Antiglaucoma Therapy.
Non Interventional Study in Slovak Patients With Primary Open Angle Glaucoma and/or Ocular Hypertension Treated With Xalacom® After Failure of Previous Antiglaucoma Therapy Due to Ineffectivity or Intolerance.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 457 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to evaluate the safety and tolerability of Xalacom in patients with primary glaucoma
Detailed description
according to physicians decision, patients who met inclusion and exclusion criteria and sign the ICD
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Xalacom | Xalacom 1 drop into the affected eye daily |
Timeline
- Start date
- 2008-10-01
- Primary completion
- 2009-06-01
- Completion
- 2009-06-01
- First posted
- 2008-12-03
- Last updated
- 2021-02-18
Locations
39 sites across 1 country: Slovakia
Source: ClinicalTrials.gov record NCT00801437. Inclusion in this directory is not an endorsement.